https://www.selleckchem.com/products/yo-01027.html
There were 133 amputations in CREDENCE (3·0% annual event rate) and 187 amputations in CANVAS (1·8% annual event rate), with prior amputation being the strongest predictor of future amputation in both groups. Effects of canagliflozin on amputation risk were significantly different between trials (pheterogeneity 0·02, I2 =82%), but this was not explained by participant or trial differences. There was no evidence that foot disease management protocols instituted during CREDENCE ameliorated amputation risk. Conclusions We identified no ex
Like
Comment
Share
